REPORT HIGHLIGHT
Chinese hamster ovary cells (CHO) market size was valued at USD 260.9 Million in 2022, expanding at a CAGR of 10.3% from 2023 to 2030.
The Chinese hamster ovaries have been utilized to produce the cell line referred to as CHO cells. In addition, they are commonly used mammalian hosts in medical and biological research, particularly for producing human therapeutic proteins. CHO cells can also be enduring post-translational changes that are human-compatible, making them excellent for pharmaceutical and medicinal applications like protein production. Moreover, CHO cells are a valuable tool in the biopharmaceutical industry owing to their ability to produce delicate recombinant proteins.
Chinese Hamster Ovary Cells (CHO) Market - Market Dynamics:
- Rising use in genetic study and continuous development will drive the demand
- The demand for CHO cells will accelerate due to the rising use of genetics studies. In addition, the CHO cell has become a standard source of cells because of the vigorous proliferation as adherent cells or in suspension. They can also adapt easily to genetic changes, thus used for genetic studies. The rising demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic proteins, is an essential driver for the CHO cell market. Moreover, for producing these complex biologics CHO cells are the preferred host cells owing to their ability to secrete and express high yields of recombinant proteins.
- However, meeting regulatory standards, such as Good Manufacturing Practices (GMP), may be time-consuming and challenging which is likely to restrain the market growth. Furthermore, technological advancements in cell culture, such as bioreactors, cell culture systems, and media formulations offer opportunities for enhancing the efficiency and productivity of CHO cell-based bioprocessing. In line with this, in this field innovations contribute to optimized biopharmaceutical production and improved cell culture performance. As a result, above mention factors are likely to propel the growth of the CHO cell market.
Chinese Hamster Ovary Cells (CHO) Market - Key Insights:
- As per the analysis shared by our research analyst, the global Chinese hamster ovary cells market is estimated to grow annually at a CAGR of around 10.3% over the forecast period (2023-2030)
- The Chinese hamster ovary cells industry is projected to grow at a significant rate due to the rising use of genetics studies
- Based on product type segmentation, CHO- DG44 was predicted to show maximum market share in the year 2022
- Based on system segmentation, antibiotic selection system was the leading type in 2022
- High yields of recombinant proteins, like therapeutic enzymes and monoclonal antibodies, can efficiently produced by CHO cells
Chinese Hamster Ovary Cells (CHO) Market- Segmentation Analysis:
- The global Chinese hamster ovary cells (CHO) market is segmented on the basis of product type, system, application, end- users, and region.
- The market is divided into four categories based on product type: CHO- DG44, CHO-DXB1, CHO-K1, CHO-S, and Others. The CHO-DG44 segment is expected to witness speedy growth as these cells are a selective subline of CHO cells. Moreover, DG44 cells a host cell line have been engineered to develop recombinant protein production.
- The market is divided into two categories based on the system: metabolic selection system and antibiotic selection system. The antibiotic selection system segment is accounted to dominate the largest market share. An antibiotic selection system is employed to maintain cells that have been genetically engineered or modified. Moreover, these cells majorly include introducing a gene that confers resistance to a particular antibiotic. In the presence of the antibiotic, transformed cells will survive while non-transformed cells will die.
- The market is divided into six categories based on application: hormones, monoclonal antibodies, FC- fusion protein, clotting factors, cytokines, enzymes, and others. The Fc-fusion protein segment is anticipated to hold the largest revenue share. An Fc-fusion protein is a variety of recombinant proteins that combines the Fc (fragment crystallizable) region of an antibody with another protein of interest. A type of recombinant protein termed as an Fc-fusion protein that combines the Fc (fragment crystallizable) region of an antibody with an alternate protein of interest. Moreover, this segment can confer increased stability, improved pharmacokinetic properties to the protein of interest, and a longer half-life in circulation.
- The market is divided into five categories based on end-users: biotech companies, biopharmaceutical companies, clinical development & manufacturing organization, academic institutes and research, clinical research organizations, and others. The biopharmaceutical companies segment is likely to maintain its dominance over the forecast period. In the development of technology rising number of applications and increasing government investments will likely expand the market's growth rate. Moreover, owing to the huge acceptance by the human system, the market's growth rate will further influence it, because they have the same therapeutics produced in humans.
Chinese Hamster Ovary Cells (CHO) Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Chinese Hamster Ovary Cells (CHO) Market- Competitive Landscape:
The rise in favorable government policies and in research and development spending regarding healthcare infrastructure will increase market growth. Moreover, in the development of technology increasing government investments and the rising number of applications will projected to expand the market's growth rate. The market's growth rate will further influence it, owing to the huge acceptance by the human system as they have the same therapeutics produced in humans. For instance, in May 2021, WuXi Biologics global company with leading open-access biologics technology platforms announced its acquisitions of a Bayer manufacturing facility in Wuppertal, Germany, the Pfizer China ("Pfizer") manufacturing facilities in Hangzhou, China along with CMAB Biopharma Group ("CMAB").
Recent Developments:
For instance, in December 2021, a company Thermo Fisher Scientific Inc. introduces its acquisition of PPD, Inc. With the addition of PPD, Thermo Fisher will provide a comprehensive suite of world-class services in all the clinical development spectrum - from scientific discovery to assessing efficacy, safety, and health care outcomes, to the manufacturing & development of the drug product, and to managing clinical trial logistics.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET KEY PLAYERS
- Promega Corporation
- Aragen Life Sciences Pvt. Ltd.
- Thermo Fisher Scientific
- Cygnus Technologies
- Selexis SA
- trenzyme GmbH
- JSR Life Sciences, LLC
- Merck KGaA
- WuXi Biologics
- CELONIC Group
- WuXi Biologics
- ProBioGen AG
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY PRODUCT TYPE
- CHO- DG44
- CHO-DXB1
- CHO-K1
- CHO-S
- Others
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY SYSTEM
- Metabolic Selection System
- Antibiotic Selection System
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY APPLICATION
- Hormones
- Monoclonal antibodies
- Fc- Fusion Protein
- Clotting Factors
- Cytokines
- Enzymes
- Others
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY END- USERS
- Biotech Companies
- Biopharmaceutical Companies
- Clinical Development & Manufacturing Organization
- Academic Institutes and Research
- Clinical Research Organizations
- Others
GLOBAL CHINESE HAMSTER OVARY CELLS (CHO) MARKET, BY REGION
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA